Copaiba oil enhances in vitro/in vivo cutaneous permeability and in vivo anti‐inflammatory effect of celecoxib

Objectives The aim of this article was to use copaiba oil (C.O) to improve skin permeability and topical anti‐inflammatory activity of celecoxib (Cxb). Methods Formulations containing C.O (1–50%) were associated with Cxb (2%). In vitro skin permeability studies were conducted using porcine ear skin. Histological analysis of the hairless mice skin samples after application of formulations was achieved with the routine haematoxylin/eosin technique. The anti‐inflammatory activity was assessed using the AA‐induced ear oedema mice model. Key findings The formulation containing 25% C.O promoted the highest levels of in vitro Cxb permeation through pig ear skin, retention in the stratum corneum (SC) and epidermis/dermis of pig ear skin in vitro (~5‐fold) and hairless mice skin in vivo (~2.0‐fold), as compared with the control formulation. At 25%, C.O caused SC disorganization and increased cell infiltration and induced angiogenesis without clear signs of skin irritation. The formulation added to 25% C.O as adjuvant inhibited ear oedema and protein extravasation by 77.51 and 89.7%, respectively, and that it was, respectively, 2.0‐ and 3.4‐fold more efficient than the commercial diethylammonium diclofenac cream gel to suppress these inflammatory parameters. Conclusions 25% C.O is a potential penetration enhancer for lipophilic drugs like Cxb that can improve cutaneous drug penetration and its anti‐inflammatory activity.